Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Aryl hydrocarbon receptor (AHR) plays an important role in the development and maturation of many tissues. Moreover, it regulates the circadian clock by inhibiting the basal and circadian expression of the core circadian component PER1.
The AHR pipeline market research report provides comprehensive information on the AHR targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research, and development history as well as the latest news and press releases. Additionally, the report provides an overview of key players involved in Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted therapeutics development with respective active and dormant or discontinued projects.
Key Therapy Areas in the AHR Pipeline Products Market
The key therapy areas in the AHR pipeline products market are oncology, immunology, gastrointestinal, dermatology, central nervous system, infectious disease, metabolic disorders, ophthalmology, and respiratory. Oncology has the highest number of pipeline products in the AHR pipeline products market.
AHR Pipeline Products Market Analysis by Therapy Areas
For more therapy area insights, download a free report sample
Key Mechanisms of Action in the AHR Pipeline Products Market
The key mechanisms of action in the AHR pipeline products market are Aryl Hydrocarbon Receptor Agonist and Aryl Hydrocarbon Receptor Antagonist.
AHR Pipeline Products Market Analysis by Mechanisms of Action
For more mechanisms of action insights, download a free report sample
Key Routes of Administration in the AHR Pipeline Products Market
The key routes of administration in the AHR pipeline products market are oral, intravenous, inhalational, intraarticular, and topical.
AHR Pipeline Products Market Analysis by Routes of Administration
For more routes of administration insights, download a free report sample
Key Molecule Types in the AHR Pipeline Products Market
The key molecule types in the AHR pipeline products market are small molecule, biologic, synthetic peptide, cell therapy, and monoclonal antibody.
AHR Pipeline Products Market Analysis by Molecule Types
For more molecule type insights, download a free report sample
Major Companies in the AHR Pipeline Products Market
Some of the major companies in the AHR pipeline products market are Actavalon Inc, Active Biotech AB, Ampio Pharmaceuticals Inc, AnTolRx Inc, Aqilion AB, Artus Therapeutics Inc, Aslan Pharmaceuticals Ltd, Azora Therapeutics Australia Pty Ltd, Bayer AG, and Dermavant Sciences Inc.
AHR Pipeline Products Market Analysis by Companies
To know more about major companies, download a free report sample
AHR Pipeline Products Market Report Overview
Key Therapy Areas | Oncology, Immunology, Gastrointestinal, Dermatology, Central Nervous System, Infectious Disease, Metabolic Disorders, Ophthalmology, and Respiratory |
Key Mechanisms of Action | Aryl Hydrocarbon Receptor Agonist and Aryl Hydrocarbon Receptor Antagonist |
Key Routes of Administration | Oral, Intravenous, Inhalational, Intraarticular, and Topical |
Key Molecule Type | Small Molecule, Biologic, Synthetic Peptide, Cell Therapy, and Monoclonal Antibody |
Major Companies | Actavalon Inc, Active Biotech AB, Ampio Pharmaceuticals Inc, AnTolRx Inc, Aqilion AB, Artus Therapeutics Inc, Aslan Pharmaceuticals Ltd, Azora Therapeutics Australia Pty Ltd, Bayer AG, and Dermavant Sciences Inc |
Scope
- The report provides a snapshot of the global therapeutic landscape for Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR)
- The report reviews Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing, and collaboration details & other developmental activities
- The report reviews key players involved in Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted therapeutics and enlists all their major and minor projects
- The report assesses Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA), and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews the latest news and deals related to Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage
- Identify and understand the targeted therapy areas and indications for Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and their most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Active Biotech AB
Ampio Pharmaceuticals Inc
AnTolRx Inc
Aqilion AB
Artus Therapeutics Inc
Aslan Pharmaceuticals Ltd
Azora Therapeutics Australia Pty Ltd
Bayer AG
Dermavant Sciences Inc
Hercules Pharmaceuticals BV
Ikena Oncology Inc
JAGUAHR Therapeutics Pte Ltd
Magenta Therapeutics Inc
Nogra Pharma Ltd
Pfizer Inc
Phenex Pharmaceuticals AG
Shenogen Pharma Group Ltd
Sol-Gel Technologies Ltd
Welichem Biotech Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key therapy areas in the AHR pipeline products market?
The key therapy areas in the AHR pipeline products market are oncology, immunology, gastrointestinal, dermatology, central nervous system, infectious disease, metabolic disorders, ophthalmology, and respiratory.
-
What are the key mechanisms of action in the AHR pipeline products market?
The key mechanisms of action in the AHR pipeline products market are Aryl Hydrocarbon Receptor Agonist and Aryl Hydrocarbon Receptor Antagonist.
-
What are the key routes of administration in the AHR pipeline products market?
The key routes of administration in the AHR pipeline products market are oral, intravenous, inhalational, intraarticular, and topical.
-
What are the key molecule types in the AHR pipeline products market?
The key molecule types in the AHR pipeline products market are small molecule, biologic, synthetic peptide, cell therapy, and monoclonal antibody.
-
Which are the major companies in the AHR pipeline products market?
Some of the major companies in the AHR pipeline products market are Actavalon Inc, Active Biotech AB, Ampio Pharmaceuticals Inc, AnTolRx Inc, Aqilion AB, Artus Therapeutics Inc, Aslan Pharmaceuticals Ltd, Azora Therapeutics Australia Pty Ltd, Bayer AG, and Dermavant Sciences Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.